Revised proposals for the EU’s overhaul of pharma legislation have been welcomed by off-patent industry organization Medicines for Europe as offering progress, after a European Parliament committee voted to approve a modified version of the European Commission’s “pharmaceutical package.”
Published in April 2023, the package had included significant changes to regulatory data protection (RDP) periods, as well as simplified marketing authorization procedures and moves towards greater digitalization